Positive Phase 3 results from the INTerpath-001 trial, showing a 42% reduction in melanoma recurrence or death when the personalized mRNA vaccine intismeran autogene (mRNA-4157/V940) was added to Keytruda, have driven strong trader consensus on a timely BLA submission. Moderna and Merck announced the data in August 2026, released detailed findings in October at ESMO, and confirmed they are actively engaging regulators with an eye toward filing in late 2026 or early 2027. This timeline, combined with the vaccine’s Breakthrough Therapy Designation and the companies’ stated 2027 launch target, supports the market-implied odds near 87% for submission by June 30, 2027. Key upcoming catalysts include any official filing announcement or FDA acceptance, which would further solidify the outcome while leaving modest room for typical manufacturing or review delays.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật1H6H1D7D30DALL
View resolved

Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp